Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.69 |
| ▸ | KDR | P35968 | 5/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907455 | 0.84 | TGFBR1 (0.67) | TGFBR1KDRMAPK14MAPKAPK2ATR | |
| SCHEMBL5907453 | 0.82 | TGFBR1 (0.69) | TGFBR1KDRMAPK14MAPKAPK2ATR | |
| SCHEMBL6222961 | 0.82 | TGFBR1 (1.00) | TGFBR1KDRMAPK14MAPKAPK2ATR | |
| SCHEMBL6264300 | 0.82 | TGFBR1 (0.78) | TGFBR1KDRMAPK14MAPKAPK2ATR | |
| SCHEMBL5956369 | 0.81 | TGFBR1 (0.64) | TGFBR1KDRMAPK14MAPKAPK2ATR | |
| SCHEMBL5956423 | 0.80 | TGFBR1 (0.66) | TGFBR1KDRMAPK14MAPKAPK2ATR | |
| SCHEMBL5787523 | 0.79 | TGFBR1 (0.69) | TGFBR1KDRMAPK14ATR | |
| SCHEMBL20074398 | 0.78 | TGFBR1 (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074474 | 0.78 | TGFBR1 (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL20074390 | 0.78 | TGFBR1 (1.00) | TGFBR1KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | GELLIBERT FRANCOISE J | 2006-04-06 | — | — | US | claimed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | GELLIBERT FRANCOISE J | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | SMAD3, TGFBR1, SMAD2 | TGFBR1 2/4885KDR 141/4885MAPK14 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.